AMD announced its first life sciences collaboration with AI-based drug developer Absci, providing its hardware and software for Absci’s AI drug discovery. Despite AMD also investing $20m in Absci, its shares fell 4% after HSBC analyst Frank Lee downgraded the firm from “Buy” to “Reduce” and cut its price target by 18%, suggesting AMD will continue trailing market leader Nvidia. This is AMD’s first life-sciences partnership.
North Korean Hackers Use Fake U.S. Companies to Spread Malware in Crypto Industry: Report
North Korean hackers reportedly set up shell companies in the US to penetrate the crypto sector and target developers via fake job offers, according to
